Irinotecan hydrochloride/Floxuridine

盐酸伊立替康/氟尿苷

Report date: 2023/05/22 20:00:22

Base Information

Drug NameIrinotecan hydrochloride/Floxuridine
Drug Alias NameIrinotecan hydrochloride-Floxuridine盐酸伊立替康和氟尿苷盐酸伊立替康●氟尿苷Irinotecan hydrochloride+Floxuridine盐酸伊立替康-氟尿苷 +[19] 
ClassificationSmall molecules
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsSolid tumoursColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesMainland China
CombinationsYes FloxuridineIrinotecan hydrochloride
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesJazz Pharmaceuticals Plc
China Registration ClassN/A

Develop Information

Active CompaniesLuye Pharma Group Ltd
Inactive CompaniesJazz Pharmaceuticals Plc
Active IndicationsSolid tumours
Inactive IndicationsColorectal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A